Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu, China.
Stroke Vasc Neurol. 2019 Jul 4;4(2):63-66. doi: 10.1136/svn-2018-000194. eCollection 2019 Jul.
Stroke is a cerebrovascular disease displaying high mortality and morbidity. Despite extensive efforts, only very few therapies are available for stroke patients as yet. Hydrogen sulfide (HS) is thought to be a signalling molecule that is endogenously produced and plays functional roles in the central nervous system. Currently, numerous studies show that HS impacts stroke outcomes in animal and cellular models. Here, we review the recent research regarding the effects of endogenously produced HS as well as exogenous HS donors on stroke pathology, focusing on the potential of HS-based therapies in treating ischaemic stroke. We also discuss the several issues that hinder the clinical translation of HS-based therapies from the bench. Taken together, we think that HS-based therapies are promising strategies for treating cerebral ischaemia if we successfully address these issues.
中风是一种脑血管疾病，具有高死亡率和高发病率。尽管已经做出了广泛的努力，但目前可供中风患者使用的治疗方法却很少。硫化氢（HS）被认为是一种信号分子，它在中枢神经系统中内源性产生并发挥功能作用。目前，大量研究表明 HS 会影响动物和细胞模型中风的结果。在这里，我们回顾了关于内源性 HS 以及外源性 HS 供体对中风病理影响的最新研究，重点介绍了基于 HS 的治疗方法在治疗缺血性中风方面的潜力。我们还讨论了阻碍 HS 治疗方法从实验室转化为临床应用的几个问题。总的来说，如果我们能够成功解决这些问题，那么基于 HS 的治疗方法是治疗脑缺血的很有前途的策略。
